Ieq Capital LLC Buys Shares of 33,739 Gilead Sciences, Inc. $GILD

Ieq Capital LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 33,739 shares of the biopharmaceutical company's stock, valued at approximately $4,263,000.

Several other hedge funds also recently made changes to their positions in the stock. Robinhood Asset Management LLC bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $719,000. Callan Family Office LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $12,817,000. Expressive Wealth LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $868,000. Laidlaw Wealth Management LLC increased its holdings in shares of Gilead Sciences by 74.2% in the second quarter. Laidlaw Wealth Management LLC now owns 2,866 shares of the biopharmaceutical company's stock worth $362,000 after purchasing an additional 1,221 shares during the period. Finally, Shelter Mutual Insurance Co purchased a new stake in shares of Gilead Sciences in the second quarter worth $4,057,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on GILD. Weiss Ratings cut Gilead Sciences from a "buy (b-)" rating to a "hold (c-)" rating in a research report on Tuesday, August 11th. Rothschild & Co Redburn dropped their price target on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Wall Street Zen raised Gilead Sciences from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. HSBC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $155.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.04.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $146.74 on Tuesday. The stock's 50-day moving average is $132.42 and its 200 day moving average is $136.57. The stock has a market cap of $181.95 billion, a price-to-earnings ratio of -54.96 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. During the same period last year, the business earned $2.01 earnings per share. The business's quarterly revenue was up 10.6% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.51 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer directly owned 592,133 shares of the company's stock, valued at $77,160,851.23. The trade was a 2.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the sale, the director directly owned 10,066 shares of the company's stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 87,000 shares of company stock worth $11,562,960 in the last ninety days. Corporate insiders own 0.30% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source